NASDAQ:ETON Eton Pharmaceuticals (ETON) Stock Forecast, Price & News $3.86 +0.07 (+1.85%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$3.75▼$3.9450-Day Range$3.40▼$4.0852-Week Range$1.95▼$4.25Volume88,343 shsAverage Volume38,985 shsMarket Capitalization$98.35 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Eton Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside159.3% Upside$10.00 Price TargetShort InterestHealthy2.38% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.32) to $0.15 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.04 out of 5 starsMedical Sector597th out of 1,018 stocksPharmaceutical Preparations Industry293rd out of 498 stocks 3.5 Analyst's Opinion Consensus RatingEton Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Eton Pharmaceuticals has a forecasted upside of 159.3% from its current price of $3.86.Amount of Analyst CoverageEton Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.38% of the float of Eton Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEton Pharmaceuticals has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.Change versus previous monthShort interest in Eton Pharmaceuticals has recently decreased by 9.72%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEton Pharmaceuticals does not currently pay a dividend.Dividend GrowthEton Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ETON. Previous Next 3.6 News and Social Media Coverage News SentimentEton Pharmaceuticals has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Eton Pharmaceuticals this week, compared to 1 article on an average week.Search Interest1 people have searched for ETON on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eton Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.95% of the stock of Eton Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 25.09% of the stock of Eton Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Eton Pharmaceuticals are expected to grow in the coming year, from ($0.32) to $0.15 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eton Pharmaceuticals is -16.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eton Pharmaceuticals is -16.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEton Pharmaceuticals has a P/B Ratio of 8.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Eton Pharmaceuticals (NASDAQ:ETON) StockEton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection. The company was founded in April 2017 and is headquartered in Deer Park, IL.Read More Receive ETON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eton Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ETON Stock News HeadlinesMay 17, 2023 | americanbankingnews.comEton Pharmaceuticals, Inc. to Post FY2024 Earnings of $0.15 Per Share, HC Wainwright Forecasts (NASDAQ:ETON)May 16, 2023 | finance.yahoo.comEton Pharmaceuticals, Inc. (NASDAQ:ETON) Q1 2023 Earnings Call TranscriptMay 27, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 12, 2023 | marketwatch.com8-K: Eton Pharmaceuticals, Inc.May 11, 2023 | msn.comRecap: Eton Pharmaceuticals Q1 EarningsMay 11, 2023 | finance.yahoo.comEton Pharmaceuticals, Inc. (ETON) Reports Q1 Loss, Tops Revenue EstimatesMay 11, 2023 | finance.yahoo.comEton Pharmaceuticals Reports First Quarter 2023 Financial ResultsMay 10, 2023 | finance.yahoo.comEton Pharmaceuticals Announces Commercial Availability of Betaine Anhydrous for Oral Solution, a Generic Version of Cystadane® (betaine anhydrous for oral solution)May 27, 2023 | Behind the Markets (Ad)The 4th Military Revolution is Happening. There have been 3 military revolutions in the past 100 years. The first was when the tank was invented in 1915. The second was the nuclear bomb in 1945. The third was the "smart bomb" in 1991. Amid the turmoil, there will be many losers. Click here to see how to win instead >>>May 10, 2023 | americanbankingnews.comEton Pharmaceuticals (ETON) to Release Earnings on ThursdayMay 4, 2023 | finance.yahoo.comGT Biopharma Names Charles J. Casamento to the Board of DirectorsMay 3, 2023 | finance.yahoo.comEton Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023April 19, 2023 | finance.yahoo.comGetting In Cheap On Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Might Be DifficultMarch 24, 2023 | marketwatch.comAllergic Conjunctivitis Market Top Players by 2031March 23, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Lowered by HC WainwrightMarch 23, 2023 | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for Eton Pharmaceuticals (NASDAQ:ETON)March 22, 2023 | americanbankingnews.comBrokers Issue Forecasts for Eton Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:ETON)March 22, 2023 | americanbankingnews.comEton Pharmaceuticals, Inc. (NASDAQ:ETON) Expected to Earn Q1 2024 Earnings of ($0.01) Per ShareMarch 22, 2023 | seekingalpha.comEton Pharmaceuticals Has Some Potential As A Speculative PlayMarch 21, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Eton Pharmaceuticals (ETON)March 18, 2023 | seekingalpha.comEton Pharmaceuticals, Inc. (ETON) Q4 2022 Earnings Call TranscriptMarch 18, 2023 | finance.yahoo.comEton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2022 Earnings Call TranscriptMarch 17, 2023 | msn.comGoHealthEPS of -$7.00, revenue of $69.38MMarch 16, 2023 | msn.comEton Pharmaceuticals, Inc. (ETON) Q4 Earnings Surpass EstimatesMarch 16, 2023 | finance.yahoo.comEton Pharmaceuticals Reports Fourth Quarter 2022 Financial ResultsMarch 15, 2023 | markets.businessinsider.comHere's what Wall Street expects from Eton Pharmaceuticals's earningsMarch 15, 2023 | msn.comA Preview Of Eton Pharmaceuticals's EarningsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ETON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eton Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ETON Company Calendar Last Earnings3/16/2023Today5/27/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ETON CUSIPN/A CIK1710340 Webwww.etonpharma.com Phone(847) 787-7361FaxN/AEmployees17Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.00 High Stock Price Forecast$10.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+159.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,020,000.00 Net Margins-26.05% Pretax Margin-26.05% Return on Equity-52.12% Return on Assets-27.16% Debt Debt-to-Equity Ratio0.45 Current Ratio2.55 Quick Ratio2.49 Sales & Book Value Annual Sales$21.25 million Price / Sales4.63 Cash FlowN/A Price / Cash FlowN/A Book Value$0.44 per share Price / Book8.77Miscellaneous Outstanding Shares25,500,000Free Float22,966,000Market Cap$98.35 million OptionableNot Optionable Beta1.45 Key ExecutivesSean E. BrynjelsenPresident, Chief Executive Officer & DirectorJames R. GruberChief Financial Officer, Secretary & TreasurerDavid KrempaChief Business OfficerKevin GuthrieExecutive Vice President-Commercial OperationsIngrid HoosSenior Vice President-Regulatory AffairsKey CompetitorsKronos BioNASDAQ:KRONBriaCell TherapeuticsNASDAQ:BCTXTransCode TherapeuticsNASDAQ:RNAZLeap TherapeuticsNASDAQ:LPTXSpero TherapeuticsNASDAQ:SPROView All CompetitorsInsiders & InstitutionsWestside Investment Management Inc.Sold 36,900 shares on 5/17/2023Ownership: 2.029%Susquehanna International Group LLPSold 16,936 shares on 5/16/2023Ownership: 0.043%Lido Advisors LLCBought 44,000 shares on 5/15/2023Ownership: 0.173%Blair William & Co. ILSold 3,157 shares on 5/12/2023Ownership: 0.137%Renaissance Technologies LLCBought 13,400 shares on 5/12/2023Ownership: 0.053%View All Insider TransactionsView All Institutional Transactions ETON Stock - Frequently Asked Questions Should I buy or sell Eton Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eton Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ETON shares. View ETON analyst ratings or view top-rated stocks. What is Eton Pharmaceuticals' stock price forecast for 2023? 1 equities research analysts have issued 12-month price objectives for Eton Pharmaceuticals' shares. Their ETON share price forecasts range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next twelve months. This suggests a possible upside of 159.3% from the stock's current price. View analysts price targets for ETON or view top-rated stocks among Wall Street analysts. How have ETON shares performed in 2023? Eton Pharmaceuticals' stock was trading at $2.82 on January 1st, 2023. Since then, ETON shares have increased by 36.8% and is now trading at $3.8570. View the best growth stocks for 2023 here. Are investors shorting Eton Pharmaceuticals? Eton Pharmaceuticals saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 530,400 shares, a decline of 9.7% from the April 30th total of 587,500 shares. Based on an average daily volume of 47,900 shares, the days-to-cover ratio is currently 11.1 days. Approximately 2.4% of the company's shares are short sold. View Eton Pharmaceuticals' Short Interest. When is Eton Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our ETON earnings forecast. How were Eton Pharmaceuticals' earnings last quarter? Eton Pharmaceuticals, Inc. (NASDAQ:ETON) issued its earnings results on Thursday, March, 16th. The company reported $0.04 EPS for the quarter, beating analysts' consensus estimates of $0.01 by $0.03. The company had revenue of $8.50 million for the quarter, compared to analysts' expectations of $9.10 million. Eton Pharmaceuticals had a negative trailing twelve-month return on equity of 52.12% and a negative net margin of 26.05%. What other stocks do shareholders of Eton Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eton Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Myovant Sciences (MYOV), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC) and Moderna (MRNA). When did Eton Pharmaceuticals IPO? (ETON) raised $22 million in an initial public offering on Wednesday, November 14th 2018. The company issued 3,600,000 shares at a price of $6.00 per share. National Securities Corporation served as the underwriter for the IPO. What is Eton Pharmaceuticals' stock symbol? Eton Pharmaceuticals trades on the NASDAQ under the ticker symbol "ETON." Who are Eton Pharmaceuticals' major shareholders? Eton Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Westside Investment Management Inc. (2.03%), Acuitas Investments LLC (1.84%), Stratos Wealth Partners LTD. (0.36%), Lido Advisors LLC (0.17%), Blair William & Co. IL (0.14%) and Renaissance Technologies LLC (0.05%). Insiders that own company stock include Harrow Health, Inc, Opaleye Management Inc, Pharmaceutical Co Ltd Takeda and Sean Brynjelsen. View institutional ownership trends. How do I buy shares of Eton Pharmaceuticals? Shares of ETON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Eton Pharmaceuticals' stock price today? One share of ETON stock can currently be purchased for approximately $3.86. How much money does Eton Pharmaceuticals make? Eton Pharmaceuticals (NASDAQ:ETON) has a market capitalization of $98.35 million and generates $21.25 million in revenue each year. The company earns $-9,020,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis. How can I contact Eton Pharmaceuticals? Eton Pharmaceuticals' mailing address is 21925 W. FIELD PARKWAY SUITE 235, DEER PARK IL, 60010. The official website for the company is www.etonpharma.com. The company can be reached via phone at (847) 787-7361 or via email at investorrelations@etonpharma.com. This page (NASDAQ:ETON) was last updated on 5/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eton Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.